RNS Number : 3407B
Hutchmed (China) Limited
19 March 2025
 

Press Release

 

Publication of Form 20-F

 

 

Hong Kong, Shanghai & Florham Park, NJ: Wednesday, March 19, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today published the Form 20-F for the financial year ended December 31, 2024. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/3407B_1-2025-3-19.pdf and also on the website of the Company at www.hutch-med.com.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, and the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

 

CONTACTS

Investor Enquiries

+852 2121 8200 / ir@hutch-med.com



Media Enquiries


FTI Consulting -

+44 20 3727 1030 / HUTCHMED@fticonsulting.com

   Ben Atwell / Alex Shaw

   +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)

Brunswick - Zhou Yi

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com



Panmure Liberum

Nominated Advisor and Joint Broker

Atholl Tweedie / Freddy Crossley / Rupert Dearden

+44 20 7886 2500



HSBC

Joint Broker

Simon Alexander / Alina Vaskina / Arnav Kapoor

+44 20 7991 8888



Cavendish

Joint Broker

Geoff Nash / Nigel Birks

+44 20 7220 0500

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAPKCBBNBKDDND